AU2008264890A1 - Variegin from amblyomma variegatum is a direct thrombin inhibitor - Google Patents

Variegin from amblyomma variegatum is a direct thrombin inhibitor Download PDF

Info

Publication number
AU2008264890A1
AU2008264890A1 AU2008264890A AU2008264890A AU2008264890A1 AU 2008264890 A1 AU2008264890 A1 AU 2008264890A1 AU 2008264890 A AU2008264890 A AU 2008264890A AU 2008264890 A AU2008264890 A AU 2008264890A AU 2008264890 A1 AU2008264890 A1 AU 2008264890A1
Authority
AU
Australia
Prior art keywords
thrombin
seq
variegin
exosite
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008264890A
Other languages
English (en)
Inventor
Maria Kazimirova
R. Manjunatha Kini
Cho Yeow Koh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natural Environment Research Council
Original Assignee
INST OF ZOOLOGY OF SLOVAK
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST OF ZOOLOGY OF SLOVAK, National University of Singapore filed Critical INST OF ZOOLOGY OF SLOVAK
Publication of AU2008264890A1 publication Critical patent/AU2008264890A1/en
Assigned to NATIONAL ENVIRONMENT RESEARCH COUNCIL reassignment NATIONAL ENVIRONMENT RESEARCH COUNCIL Request for Assignment Assignors: INSTITUTE OF ZOOLOGY OF THE SLOVAK ACADEMY OF SCIENCES, NATIONAL UNIVERSITY OF SINGAPORE
Assigned to NATURAL ENVIRONMENT RESEARCH COUNCIL reassignment NATURAL ENVIRONMENT RESEARCH COUNCIL Amend patent request/document other than specification (104) Assignors: NATIONAL ENVIRONMENT RESEARCH COUNCIL
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2008264890A 2007-06-18 2008-06-18 Variegin from amblyomma variegatum is a direct thrombin inhibitor Abandoned AU2008264890A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0711779.9 2007-06-18
GBGB0711779.9A GB0711779D0 (en) 2007-06-18 2007-06-18 Thrombin inhibitor
PCT/IB2008/002109 WO2008155658A2 (en) 2007-06-18 2008-06-18 Thrombin inhibitor

Publications (1)

Publication Number Publication Date
AU2008264890A1 true AU2008264890A1 (en) 2008-12-24

Family

ID=38332312

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008264890A Abandoned AU2008264890A1 (en) 2007-06-18 2008-06-18 Variegin from amblyomma variegatum is a direct thrombin inhibitor

Country Status (8)

Country Link
US (1) US9217027B2 (enExample)
EP (1) EP2185185B1 (enExample)
JP (1) JP5699393B2 (enExample)
CN (1) CN102026652B (enExample)
AU (1) AU2008264890A1 (enExample)
CA (1) CA2691243A1 (enExample)
GB (1) GB0711779D0 (enExample)
WO (1) WO2008155658A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102225966B (zh) 2004-10-19 2012-12-26 隆萨股份公司 用于固相肽合成的方法
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor
GB0907698D0 (en) * 2009-05-05 2009-06-10 Univ Singapore Method of modifying serine protease inhibitors
US10299714B2 (en) 2010-12-02 2019-05-28 Becton, Dickinson And Company Blood collection devices containing blood stabilization agent including variegin or analog thereof and/or a polysulfated disaccharide
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
US20140220552A1 (en) * 2013-02-01 2014-08-07 Becton, Dickinson And Company Blood collection devices containing contact pathway inhibition additives
GB201310948D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Screening methods
GB201406863D0 (en) * 2014-04-16 2014-05-28 Univ Leeds Compositions comprising variegin
WO2015191632A1 (en) 2014-06-10 2015-12-17 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
RU2745847C2 (ru) * 2015-06-18 2021-04-01 Нэшнл Юниверсити Оф Сингапур Новые ингибиторы тромбина
WO2017100212A1 (en) 2015-12-08 2017-06-15 Biomatrica, Inc. Reduction of erythrocyte sedimentation rate
AU2017376839B2 (en) * 2016-12-16 2021-01-14 IBMC (Instituto de Biologia Molecular e Cellular) Thrombin inhibitors for treatment of stroke and related coagulative disorders
BR102017005783A2 (pt) 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
ES3020087T3 (en) * 2020-09-21 2025-05-21 Instr Laboratory Co Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341032C (en) 1987-01-23 2000-06-20 John L. Krstenansky Anticoagulant peptides
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
US6060451A (en) 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
WO1995011921A1 (en) 1993-10-25 1995-05-04 National Research Council Of Canada Bivalent thrombin inhibitors
AU3479495A (en) 1994-09-30 1996-04-26 Ppl Therapeutics (Scotland) Ltd Alpha-1-antitrypsin and antithrombine-iii variants
GB9506212D0 (en) 1995-03-27 1995-05-17 Iaf Biochem Int Bifunctional thrombin inhibitors bearing highly truncated fibrinogen recognition exosite binding component
GB9613718D0 (en) 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
GB0209249D0 (en) 2002-04-23 2002-06-05 Evolutec Ltd Anticoagulants
US7456152B2 (en) 2003-02-27 2008-11-25 National Research Council Of Canada Peptide inhibitors of thrombin as potent anticoagulants
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor

Also Published As

Publication number Publication date
CN102026652A (zh) 2011-04-20
CA2691243A1 (en) 2008-12-24
WO2008155658A2 (en) 2008-12-24
US9217027B2 (en) 2015-12-22
US20130183237A1 (en) 2013-07-18
EP2185185B1 (en) 2016-05-04
JP2010530238A (ja) 2010-09-09
WO2008155658A8 (en) 2009-09-03
WO2008155658A3 (en) 2010-03-04
GB0711779D0 (en) 2007-07-25
CN102026652B (zh) 2014-06-04
JP5699393B2 (ja) 2015-04-08
EP2185185A2 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
US9217027B2 (en) Thrombin inhibitor
EP0815139B1 (en) Thrombin inhibitors based on the amino acid sequence of hirudin
CA2079778C (en) Inhibitors of thrombin
US20120135931A1 (en) Method of modifying serine protease inhibitors
Salzet Leech thrombin inhibitors
EP2123670A1 (en) Anticoagulant polypeptide
Dodt Anticoagulatory substances of bloodsucking animals: from hirudin to hirudin mimetics
EP3310807B1 (en) Novel thrombin inhibitors
US7615527B2 (en) Peptides which modulate blood coagulation and methods of use thereof
Sutherland et al. The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of α1-proteinase inhibitor M358R for thrombin
Iyer et al. Leading Article: Cardiovascular & Renal: Recombinant hirudin: A perspective
US5723576A (en) Thrombin inhibitors, the preparation thereof and the use thereof for therapeutical, prophylactic and diagnostic applications
Callas et al. Fibrinolytic compromise by synthetic and recombinant thrombin inhibitors: implications in the treatment of thrombotic disorders
Di Maio Hirudin and hirudin fragments form the basis of new antithrombotics and anticoagulants
Di Maio and anticoagulants
HK1254691B (en) Novel thrombin inhibitors
HK1005511B (en) Thrombin inhibitors based on the amino acid sequence of hirudin

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NATIONAL ENVIRONMENT RESEARCH COUNCIL

Free format text: FORMER APPLICANT(S): INSTITUTE OF ZOOLOGY OF THE SLOVAK ACADEMY OF SCIENCES; NATIONAL UNIVERSITY OFSINGAPORE

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application